Triormon_Depositum

Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate

Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate

Combination drug

Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate (EDBu/OHPH/TCa), sold under the brand name Triormon Depositum, is an injectable combination medication of estradiol dibutyrate (EDBu), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone caproate (TCa), an androgen/anabolic steroid, which was used in the treatment of menopausal symptoms in women.[1] It contained 3 mg EDBu, 30 mg OHPH, and 50 mg TCa in oil solution and was administered by intramuscular injection.[1] The medication was developed by 1957.[1] It is no longer available.[2][3]

Quick Facts Combination of, Hydroxyprogesterone heptanoate ...

See also

References

  1. [1]
    Ermiglia G, Valli P (May 1957). "Studio sul triormon depositum nella sindrome climaterica; curve di eliminazione dei cataboliti e durata dell'effetto terapeutico" [Study of tribormone depositum in the climacteric syndrome; catabolite elimination curves and duration of the therapeutic effect]. Quaderni di Clinica Ostetrica e Ginecologica (in Italian). 12 (5): 284–93. ISSN 0033-491X. PMID 13465973. Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory.
  2. [2]
    "Home". micromedexsolutions.com.
  3. [3]
    [dead link]


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Triormon_Depositum, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.